IGF-I inhibition of apoptosis is associated with decreased expression of prostate apoptosis response-4

J Endocrinol. 2007 Jul;194(1):77-85. doi: 10.1677/JOE-07-0073.

Abstract

The neuronal damage caused by ischemic brain injury is associated with increased apoptosis. IGF-I exposure promotes neuronal defense and survival against ischemic insult by inhibiting apoptotic processes. We investigated the role of prostate apoptosis response-4 (Par-4), a proapoptotic gene the expression of which is increased after ischemic injury, in IGF-I-mediated inhibition of apoptosis using PC12 cells exposed to oxygen-glucose deprivation (OGD). The OGD insult resulted in significant increases in apoptotic cell death and Par-4 expression, which were prevented by the treatment of cells with an antisense oligonucleotide of Par-4. IGF-I treatment prior to OGD insult significantly reduced the number of apoptotic cells and the OGD-induced increase in Par-4 expression. OGD-induced nuclear translocation of Par-4 was also attenuated by IGF-I treatment. In addition, we demonstrated that the anti-apoptotic effect of IGF-I was blocked by chemical inhibition of a mitogen activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), or protein kinase A (PKA), but not by a protein kinase C inhibitor. Finally, pretreatment of cells with a MAPK or PI3K inhibitor attenuated IGF-I-induced inhibition of Par-4 expression, suggesting that the MAPK and PI3K pathways contribute to IGF-I-induced Par-4 suppression. In contrast, a PKA inhibitor failed to alter the inhibitory effect of IGF-I on Par-4. These findings indicate that in PC12 cells exposed to OGD insult, IGF-I protects cells from apoptosis, at least in part through the inhibition of Par-4 expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Androstadienes / pharmacology
  • Animals
  • Apoptosis / drug effects
  • Apoptosis Regulatory Proteins / genetics
  • Apoptosis Regulatory Proteins / metabolism*
  • Biological Transport / drug effects
  • Cell Line
  • Chromones / pharmacology
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Enzyme Inhibitors / pharmacology
  • Flavonoids / pharmacology
  • Immunohistochemistry
  • Indoles / pharmacology
  • Insulin-Like Growth Factor I / pharmacology*
  • Isoquinolines / pharmacology
  • Male
  • Maleimides / pharmacology
  • Microscopy, Confocal
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
  • Morpholines / pharmacology
  • Neurons / metabolism*
  • Neurons / pathology
  • Oligonucleotides, Antisense / pharmacology
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Kinase C / antagonists & inhibitors
  • Rats
  • Recombinant Proteins / pharmacology
  • Stroke / metabolism*
  • Stroke / pathology
  • Sulfonamides / pharmacology
  • Wortmannin

Substances

  • Androstadienes
  • Apoptosis Regulatory Proteins
  • Chromones
  • Enzyme Inhibitors
  • Flavonoids
  • Indoles
  • Isoquinolines
  • Maleimides
  • Morpholines
  • Oligonucleotides, Antisense
  • Phosphoinositide-3 Kinase Inhibitors
  • Recombinant Proteins
  • Sulfonamides
  • prostate apoptosis response-4 protein
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Insulin-Like Growth Factor I
  • Cyclic AMP-Dependent Protein Kinases
  • Protein Kinase C
  • Mitogen-Activated Protein Kinase Kinases
  • bisindolylmaleimide I
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Wortmannin